Further trials of vercimon in Crohn's disease on hold

The rates of serious adverse events and withdrawals due to adverse events in the SHIELD-1 trial for vercimon in Crohn's disease, were similar among the treatment groups, but there was a trend for dose-dependent increases in overall adverse event rates. GSK will continue to explore the safety and efficacy results to inform decisions about the clinical development programme for vercirnon. New recruitment and dosing in the ongoing clinical programme has been suspended pending further review of the SHIELD-1 results.